

Fecha del CVA	
---------------	--

Parte A. DATOS PERSONALES

Nombre *	Ricardo Enrique		
Apellidos *	Pérez Tomás		
Sexo *	Hombre	Fecha de Nacimiento *	18/09/19
DNI/NIE/Pasaporte *	743364	Teléfono *	934024288
URL Web			
Dirección Email	rperez@ub.edu		
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0003-3226-1240	
	Researcher ID		
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto	Catedrático de Universidad		
Fecha inicio	2019		
Organismo / Institución	Universitat de Barcelona		
Departamento / Centro	Facultad de Medicina y Ciencias de la Salud / Departamento de Patología y Terapéutica Experimental		
País	España	Teléfono	934024288
Palabras clave			

A.4. Indicadores generales de calidad de la producción científica

Total citations (RG): 4471. RG score: 40,23 . H index: 36. Director of 11 Doctoral thesis in the last 10 years.

Tramos de investigación -autonómicos y estatales: 6. Evaluator grant programs, research projects National Agency for Evaluation and Prospective of Spain (ANEP), Expert evaluator of grant programs from different autonomic governments inside Spain: Agencia Andaluza del Conocimiento, Junta de Castilla y León, AQU Catalunya (Agencia para la Calidad del sistema Universitario de Cataluña), Agència Valenciana d'Avaluació i Prospectiva (AVAP).

Evaluator of the doctoral program in Biomedical Sciences at the Universidad de Chile 2016 and Evaluator of the "Research Grants Council (RGC) of Hong Kong" 2017.

Regular referee (10-15 manuscript/year): Biochemical Pharmacology, Food and Chemical Toxicology, International Journal of Cancer, International Journal Biochemistry& Cell Biology, British Journal of Cancer, Biochemical Journal, Pharmacological Research.

Member of the editorial board of the following journals: Current Medicinal Chemistry, Pharmaceuticals, Biomedicines, Open Lung Cancer Journal.

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Most of my independent career involved the study of cancer cell biology process like proliferation or apoptosis in order to understand it better and looking for the best way to trigger it using different cancer models. In the last 25 years I was devoted to apply small-molecule anion transporters like prodigiosin and/or obatoclax. This research was conducted by my own research group or in collaboration with other groups like Prof. James Lambert, Dept. of Pathology, University of Colorado Denver and Health Science Center, Aurora, Colorado and Prof. Alnawaz Rehemtulla from the Department of Radiation Oncology, University of Michigan Medical School.

On the other hand, in order to identify new molecules with the same nature and with therapeutic interest in the treatment of cancer, some years ago my research group started the collaboration with the Organic Chemistry Group lead by Prof. Roberto Quesada at the University of Burgos and with Prof. Phil Gale from the Chemistry Dept. at the University of Southampton (UK). We have already obtained significant results that offer proof of concept for this idea of using anion transporters as cancer chemotherapeutic agents. Our latest results involved the study of marine alkaloid tambjamins as anion transporters. We have found that these compounds and synthetic analogues are potent anion transporters and that their biological activity correlates well with their anion transport properties.

During this last period of 5 years we published 24 articles in international journals, 43 participations in conferences, several conferences and the granting of a research project (FISS: PI1000338); some of these articles have been published in collaboration with groups of organic chemistry led by Phil Gale (Southampton-UK) and Roberto Quesada (Univ. of Burgos) in prestigious journals like Chem. Comm., JACS and Account Chemical Research. We have also been able to recently make a patent application of derivatives of the tambjamins as anticancer agents (request: P201201039). I have been director of several works of Master in biomedical experimental science that replaced the dissertations and in all of them the students obtained the highest rating. Finally indicate that I have directed 11 doctoral theses all they obtained the highest rating highlighting. My experience in these 25 years in the development of compounds with anticancer properties surely it will help in the success of the present research project.

Complete list of published work at: <https://www.ub.edu/cellbiology>

Parte C. MÉRITOS MÁS RELEVANTES

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

- 1 **Artículo científico**. Pérez-Hernández, M.; Cuscó, C.; Benítez-García, C.; et al; Pérez-Tomás, R. (AC). (14/14). 2021. Multi-smart and scalable bioligands-free nanomedical platform for intratumorally targeted tambjamine delivery, a difficult to administrate highly cytotoxic drug 919478 - Biomedicines. MDPI. 9-5, pp.508. ISSN 2227-9059. <https://doi.org/10.3390/biomedicines9050508>
- 2 **Artículo científico**. Israel Carreira-Barral; Marcin Mielczarek; Daniel Alonso-Carrillo; et al; Ricardo Pérez Tomás; Roberto Quesada.(6/9). 2020. Click-tambjamins as efficient and tunable bioactive anion transporters.909184 - Chemical Communications. Royal Society of Chemistry. 56, pp.3218-3221. ISSN 1359-7345. <https://doi.org/10.1039/d0cc00643b>
- 3 **Artículo científico**. Martínez-García, D.; Pérez-Hernández, M.; Korrodi-Gregório, L.; Quesada, R.; Ramos, R.; Baixeras, N.; Pérez-Tomás, R.; Soto-Cerrato, V.(/8). 2019. The natural-based antitumor compound T21 decreases survivin levels through potent STAT3 inhibition in lung cancer models 919151 - Biomolecules. MDPI. 9-8, pp.361. ISSN 2218-273X. <https://doi.org/10.3390/biom9080361>
- 4 **Artículo científico**. Hernando, E.; Capurro, V.; Cossu, C.; et al; Pérez-Tomás, R.; Quesada, R.(7/10). 2018. Small molecule anionophores promote transmembrane anion permeation matching CFTR activity 917079 - Scientific Reports. Nature Publishing Group. 8. ISSN 2045-2322. <https://doi.org/10.1038/s41598-018-20708-3>
- 5 **Artículo científico**. Hernando, E.; Capurro, V.; Cossu, C.; et al; Pérez-Tomás, R.; Quesada, R.(7/10). 2018. Small molecule anionophores promote transmembrane anion permeation matching CFTR activity. Scientific Reports. Nature Publishing Group. ISSN 2045-2322.
- 6 **Artículo científico**. Jowett, L.A.; Howe, E.N.W.; Soto-Cerrato, V.; Van Rossom, W.; Pérez-Tomás, R.; Gale P.A.(5/6). 2017. Indole-based perenosins as highly potent HCl transporters and potential anti-cancer agents.917079 - Scientific Reports. Nature Publishing Group. 24-7, pp.9397. ISSN 2045-2322.

- 7 **Artículo científico.** Manuel-Manresa, P.; Korrodi-Gregorio, L.; Hernando, E.; et al; Perez-Tomas, R.(12/12). 2017. Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation.Molecular Cancer Therapeutics. American Association for Cancer Research. ISSN 1535-7163.
- 8 **Artículo científico.** Rodilla, A. M.; Korrodi-Gregório, L.; Hernando, E.; Manuel-Manresa, P.; Quesada, R.; Pérez-Tomás, R.; Soto-Cerrato, V.(/7). 2017. Synthetic tambjamine analogues induce mitochondrial swelling and lysosomal dysfunction leading to autophagy blockade and cell death in lung cancer 900234 - Biochemical Pharmacology. Elsevier B.V.. 126-2017, pp.23-33. ISSN 0006-2952. <https://doi.org/10.1016/j.bcp.2016.11.022>
- 9 **Revisión.** Ricardo Pérez-Tomás; Isabel Pérez-Guillén. (/9). 2020. Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment.918807 - Cancers. MDPI. 12-11, pp.3244. ISSN 2072-6694.
- 10 **Revisión.** Pérez-Hernández, M.; Arias, A.; Martínez-García, D.; Pérez-Tomás, R.; Quesada, R.; Soto-Cerrato, V.(/6). 2019. Targeting autophagy for cancer treatment and tumor chemosensitization 012862 - Cancers. MDPI. 11-10, pp.1599. ISSN 2072-6694. <https://doi.org/10.3390/cancers11101599>

C.2. Congresos

- 1 Hernando, E.; Capurro, V.; Cossu, C.; Fiore, M.; García-Valverde, M.; Soto-Cerrato, V.; Pérez-Tomás, R.; Moran, O.; Zegarra-Moran, O.; Quesada, R.. Anion transport and supramolecular medicinal chemistry. 16th Iberian Peptide Meeting 4th Chembio Group Meeting. 2018. España. Participativo - Ponencia oral (comunicación oral). Congreso.
- 2 Martínez-García, D.; Korrodi-Gregório, L.; Manero-Rupérez, N.; Manuel-Manresa, P.; Baixeras Gonzalez, N.; Ramos Izquierdo, R.; Pérez-Tomás, R.; Soto-Cerrato, V.. A novel survivin inhibitor for squamous cell lung cancer treatment. XXIV Jornada Biología Molecular. Societat Catalana de Biologia.. 16395 - Societat Catalana de Biologia. 2017. España. Participativo - Póster. Congreso.
- 3 Ramos Izquierdo, R.; Soto-Cerrato, V.; Macía Vidueira, I.; Rivas Doyague, F.; Baixeras Gonzalez, N.; Escobar Campuzano, I.; Martínez Garcia, D.; Manuel Manresa, P.; Pérez Tomás, R.; Moya Amorós, J.. Resultados preliminares sobre el efecto antineoplásico de las tambjamins sobre cultivos primarios de células neoplásicas humanas. 50º Congreso Nacional de la Sociedad Española de Neumología y Cirugía Torácica. SEPA - Separ. 2017. España. Participativo - Póster. Congreso.

C.3. Proyectos y Contratos

- 1 **Proyecto.** BU067P20, Molecular tools targeting cellular metabolism for cancer therapy.. Junta de Castilla y León. Roberto Quesada Pato. (Universidad de Burgos). 01/11/2020-31/10/2023. 264.000 €.
- 2 **Proyecto.** PI18/00441, Evaluación terapéutica preclínica en cáncer de pulmón de inhibidores de survivina mediante la utilización de formulaciones nanoencapsuladas y terapias combinadas.. FIS - Fondo de Investigación Sanitaria. Instituto de Salud Carlos III. Ricardo Pérez Tomás y Vanessa Soto Cerrato. (IDIBELL y varias entidades). 01/01/2019-31/12/2021. 87.120 €.
- 3 **Proyecto.** 2017SGR1017, Laboratori de Neurobiologia Cel·lular i Molecular. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Carles Maria Solsona Sancho. (Universitat de Barcelona). 01/01/2017-30/09/2021.
- 4 **Contrato.** Conveni de col·laboració per la recerca basada en la identificació de nous inhibidors de survivina per al tractament del càncer Universidad de Burgos; EBT Nostrum Biodiscovery, S.L.. Vanessa Soto Cerrato. (Universitat de Barcelona). 27/07/2017-27/01/2020.

C.4. Actividades de transferencia y explotación de resultados

Maria García Valverde; Vanessa Soto Cerrato; Luis Korrodi Mineiro; David Martínez García; Ricardo Pérez Tomás; Robert Soliva Soliva; Victor Guallar Tasies; Lucia Díaz Bueno; Roberto Quesada Pato. EP21382721.5. ASENAPINE FOR USE IN CANCER España. 30/07/2021. FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL).